Abdallah

Andersen

Banerji

Batra

Bertholet

Beveridge

Bold

C. Aagaard

Comas

Daku

Darrah

Davila

E. M. Agger

Elhay

G. K. Schoolnik

G. M. Dolganov

Gideon

Hoft

Kaufmann

Lindenstrom

N. P. H. Knudsen

P. Andersen

Pollock

Raviglione

Rogerson

Rowland

S. Norskov-Lauritsen

Seder

Skjot

T. Lindenstrom

Significance
          Despite the availability of a number of antibiotics and extensive use of the live vaccine bacillus Calmette–Guérin, tuberculosis remains a major global health problem. Antigen 85 is by far the most popular antigen in current clinical trials vaccines. However, a recent failure of a virus-based vaccine expressing antigen 85 emphasizes the continued need for identifying antigens, testing their protective efficacy, and learning from this process to develop a protective vaccine. The H65 vaccine demonstrates that it is possible to develop antigen 85-free vaccines that does not interfere with current immune-based diagnostic assays.</jats:p

Niels Peter H. Knudsen

Sara Nørskov-Lauritsen

Gregory M. Dolganov

Gary K. Schoolnik

Thomas Lindenstrøm

Peter Andersen

Else Marie Agger

Claus Aagaard

Crossref

Proceedings of the National Academy of Sciences

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics

Abstract

Similar works

Full text

Available Versions

Crossref